Bionano has entered into a software marketing agreement with Revvity, Inc. (Revvity) under which Revvity will market and commercialize Bionano's VIA™ software to Revvity's next generation sequencing (NGS) customers as part of its newborn sequencing research workflow VIA is expected to enhance Revvity's newborn sequencing solution by adding an assessment of copy number variation (CNV) to the NGS solution report and streamlining the workflow's interpretation capabilities Revvity's end-to-end workflow includes ...

Revvity, Inc. (RVTY) is well-poised for growth in the coming quarters, courtesy of its strong product portfolio. The optimism, led by its first-quarter 2024 performance and focus on artificial intelligence (AI), also looks promising. Headwinds resulting from foreign exchange volatility and integration risks are major downsides. This Zacks Rank #3 (Hold) company's shares have risen 0.4% year to date compared with 2.4% growth of the industry.The S&P 500 has increased 11.6% during the same time frame. The reno ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission File Number 001-5075 _______________________________________ Revvity, Inc. (Exact name of Registrant as specified in its Charter) _______________________________________ Washington, D.C. 20549 _______________________________________ FORM 10-Q _____________________________________ ...

Revvity, Inc. (RVTY) reported first-quarter 2024 adjusted earnings per share (EPS) of 98 cents, which beat the Zacks Consensus Estimate of 94 cents by 4.3%. However, the bottom line declined 2.9% from the year-ago quarter’s level.GAAP EPS from continuing operations was 23 cents compared with 20 cents in the prior-year period. However, GAAP EPS was 21 cents, which includes a loss of 2 cents per share from discontinued operations.Price PerformanceRVTY’s shares have gained 23.7% in the past six months compared ...

Revvity, Inc. (NYSE:RVTY) Q1 2024 Earnings Conference Call April 29, 2024 8:00 AM ET Company Participants Steve Willoughby - Senior Vice President, Investor Relations Prahlad Singh - President and Chief Executive Officer Max Krakowiak - Senior Vice President and Chief Financial Officer Conference Call Participants Michael Ryskin - Bank of America Matthew Sykes - Goldman Sachs Patrick Donnelly - Citi Andrew Cooper - Raymond James Joshua Waldman - Cleveland Research Doug Schenkel - Wolfe Research Vijay Kumar ...

For the quarter ended March 2024, Revvity (RVTY) reported revenue of $649.92 million, down 3.7% over the same period last year. EPS came in at $0.98, compared to $1.01 in the year-ago quarter.The reported revenue represents a surprise of +0.45% over the Zacks Consensus Estimate of $647.02 million. With the consensus EPS estimate being $0.94, the EPS surprise was +4.26%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expe ...

FOR IMMEDIATE RELEASE April 29, 2024 Revvity Announces Financial Results for the First Quarter of 2024 WALTHAM, Mass. -- Revvity, Inc. (NYSE: RVTY), today reported financial results for the first quarter ended March 31, 2024. The Company reported GAAP earnings per share of $0.21, as compared to $4.50 in the same period a year ago. GAAP revenue for the quarter was $650 million, as compared to $675 million in the same period a year ago. GAAP operating income from continuing operations for the quarter was $44 ...

Revvity (RVTY) came out with quarterly earnings of $0.98 per share, beating the Zacks Consensus Estimate of $0.94 per share. This compares to earnings of $1.01 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 4.26%. A quarter ago, it was expected that this maker of scientific instruments would post earnings of $1.15 per share when it actually produced earnings of $1.25, delivering a surprise of 8.70%.Over the last four quarters ...

Revvity, Inc. (RVTY) recently announced the launch of the Auto-Pure 2400 liquid handler from Allsheng for use with its T-SPOT.TB test. The solution, which has an intuitive software user interface, is expected to simplify lab workflows.The latest product is expected to significantly boost Revvity’s Diagnostics segment and solidify its foothold in the infectious diseases space.Significance of the LaunchPer Revvity, the easy-to-use Auto-Pure 2400 platform has been designed to provide efficient workflows in the ...

Revvity, Inc. (RVTY) recently announced that its software and informatics division, Revvity Signals, will launch Signals Synergy. Per the company, it is a software solution designed to drive greater collaboration, project management and data exchange between pharmaceutical and biotechnology sponsors with their external contract partners.Revvity is expected to officially introduce Signals Synergy at the ongoing Bio-IT World Conference & Expo in Boston, MA.The latest product is expected to significantly boost ...